Search

Your search keyword '"Picco, Agnese"' showing total 140 results

Search Constraints

Start Over You searched for: Author "Picco, Agnese" Remove constraint Author: "Picco, Agnese" Publication Type Academic Journals Remove constraint Publication Type: Academic Journals
140 results on '"Picco, Agnese"'

Search Results

1. Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer’s disease

2. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort

3. The impact of automated hippocampal volumetry on diagnostic confidence in patients with suspected Alzheimer's disease: A European Alzheimer's Disease Consortium study

4. Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers

10. Longitudinal reproducibility of default-mode network connectivity in healthy elderly participants: A multicentric resting-state fMRI study

14. Multisite longitudinal reliability of tract-based spatial statistics in diffusion tensor imaging of healthy elderly subjects

21. Test-retest reliability of the default mode network in a multi-centric fMRI study of healthy elderly: Effects of data-driven physiological noise correction techniques

22. Longitudinal reproducibility of automatically segmented hippocampal subfields: A multisite European 3T study on healthy elderly

24. Una sfida per la scienza: Genesi ed evoluzione del pensiero di Cesare Lombroso sullo spiritismo.

26. IC‐P‐006: THE INCREMENTAL VALUE OF AMYLOID PET VERSUS CSF BIOMARKERS FOR THE DIAGNOSIS OF ALZHEIMER'S DISEASE (INDIA–FBB STUDY).

27. VOLUMETRIC ACCURACY OF A FULLY AUTOMATIC TOOL FOR WHITE MATTER HYPERINTENSITIES (WMHS) SEGMENTATION

28. THE INCREMENTAL VALUE OF AMYLOID PET VERSUS CSF BIOMARKERS FOR THE DIAGNOSIS OF ALZHEIMER’S DISEASE (INDIA–FBB STUDY)

29. ACROSS-SESSION REPRODUCIBILITY OF AUTOMATIC WHITE MATTER HYPERINTENSITIES SEGMENTATION: A EUROPEAN MULTI-SITE 3T STUDY

31. IMPACT OF BIOMARKERS ON DIAGNOSTIC CONFIDENCE IN CLINICAL ASSESSMENT OF PATIENTS WITH SUSPECTED ALZHEIMER'S DISEASE AND HIGH DIAGNOSTIC UNCERTAINTY: AN EADC STUDY

32. Free water elimination improves test-retest reproducibility of diffusion tensor imaging indices in the brain: A longitudinal multisite study of healthy elderly subjects.

33. Test-retest reliability of the default mode network in a multi-centric f MRI study of healthy elderly: Effects of data-driven physiological noise correction techniques.

34. Characterization of cognitive function with the cantab in individuals with amnestic mild cognitive impairment in relation to hippocampal volume, amyloid, and tau status: Preliminary baseline results from the PharmaCog/european-ADNI study

35. Neuroimaging features in C9orf72 and TARDBP double mutation with FTD phenotype.

36. Orbitofrontal 18 F-DOPA Uptake and Movement Preparation in Parkinson’s Disease.

37. Brain F-DOPA PET and cognition in de novo Parkinson's disease.

38. Visual Versus Semi-Quantitative Analysis of 18F-FDG-PET in Amnestic MCI: An European Alzheimer's Disease Consortium (EADC) Project.

39. CROSS-SECTIONAL BIOMARKER CHARACTERIZATION OF MILD COGNITIVE IMPAIRMENT PATIENTS IN WP5 PHARMACOG/E-ADNI STUDY

40. Metabolic Correlates of Rey Auditory Verbal Learning Test in Elderly Subjects with Memory Complaints.

41. Seizures Can Precede Cognitive Symptoms in Late-Onset Alzheimer's Disease.

43. Frontal Variant Alzheimer Disease or Frontotemporal Lobe Degeneration With Incidental Amyloidosis?

44. P1‐393: THE INCREMENTAL VALUE OF AMYLOID PET VERSUS CSF BIOMARKERS FOR THE DIAGNOSIS OF ALZHEIMER'S DISEASE (INDIA–FBB STUDY).

45. IC‐P‐126: VOLUMETRIC ACCURACY OF A FULLY AUTOMATIC TOOL FOR WHITE MATTER HYPERINTENSITIES (WMHS) SEGMENTATION.

46. IC‐P‐006: THE INCREMENTAL VALUE OF AMYLOID PET VERSUS CSF BIOMARKERS FOR THE DIAGNOSIS OF ALZHEIMER'S DISEASE (INDIA–FBB STUDY).

47. Accuracy and reproducibility of automated white matter hyperintensities segmentation with lesion segmentation tool: A European multi-site 3T study.

48. White Matter Hyperintensities Are No Major Confounder for Alzheimer's Disease Cerebrospinal Fluid Biomarkers.

49. Amygdalar nuclei and hippocampal subfields on MRI: Test-retest reliability of automated volumetry across different MRI sites and vendors.

50. Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes.

Catalog

Books, media, physical & digital resources